TY - JOUR
T1 - Silica-iron oxide magnetic nanoparticles modified for gene delivery
T2 - A search for optimum and quantitative criteria
AU - Mykhaylyk, Olga
AU - Sobisch, Titus
AU - Almstätter, Isabella
AU - Sanchez-Antequera, Yolanda
AU - Brandt, Sabine
AU - Anton, Martina
AU - Döblinger, Markus
AU - Eberbeck, Dietmar
AU - Settles, Marcus
AU - Braren, Rickmer
AU - Lerche, Dietmar
AU - Plank, Christian
N1 - Funding Information:
We greatly appreciate the help of Edelburga Hammerschmid with the flow cytometry analysis and thank Dr. Uwe Vohrer and Dr. Joachim Mayer from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB for the XPS analysis of the nanomaterials. We also thank Dr. Elena Oranskaya from the Ukrainian Academy of Sciences for her help with the X-ray diffraction. Financial support from the German Research Foundation through the DFG Research Unit FOR917 (Projects PL 281/3-1, TR 408/6-1 and AN 333/1-1) and the German Excellence Cluster m4 entitled “Nanosystems Initiative Munich”, the German Federal Ministry of Education (Project ELA 10/002) and the German Federal Ministry of Economics (Project 0327414C, LUM) are gratefully acknowledged.
PY - 2012/5
Y1 - 2012/5
N2 - Purpose: To optimize silica-iron oxide magnetic nanoparticles with surface phosphonate groups decorated with 25-kD branched polyethylenimine (PEI) for gene delivery. Methods: Surface composition, charge, colloidal stabilities, associations with adenovirus, magneto-tranduction efficiencies, cell internalizations, in vitro toxicities and MRI relaxivities were tested for the particles decorated with varying amounts of PEI. Results: Moderate PEI-decoration of MNPs results in charge reversal and destabilization. Analysis of space and time resolved concentration changes during centrifugation clearly revealed that at >5% PEI loading flocculation gradually decreases and sufficient stabilization is achieved at >10%. The association with adenovirus occurred efficiently at levels over 5% PEI, resulting in the complexes stable in 50% FCS at a PEI-to-iron w/w ratio of ≥7%; the maximum magneto-transduction efficiency was achieved at 9-12%PEI. Primary silica iron oxide nanoparticles and those with 11.5% PEI demonstrated excellent r2* relaxivity values (>600 s-1(mM Fe)-1) for the free and cell-internalized particles. Conclusions: Surface decoration of the silica-iron oxide nanoparticles with a PEI-to-iron w/w ratio of 10-12% yields stable aqueous suspensions, allows for efficient viral gene delivery and labeled cell detection by MRI.
AB - Purpose: To optimize silica-iron oxide magnetic nanoparticles with surface phosphonate groups decorated with 25-kD branched polyethylenimine (PEI) for gene delivery. Methods: Surface composition, charge, colloidal stabilities, associations with adenovirus, magneto-tranduction efficiencies, cell internalizations, in vitro toxicities and MRI relaxivities were tested for the particles decorated with varying amounts of PEI. Results: Moderate PEI-decoration of MNPs results in charge reversal and destabilization. Analysis of space and time resolved concentration changes during centrifugation clearly revealed that at >5% PEI loading flocculation gradually decreases and sufficient stabilization is achieved at >10%. The association with adenovirus occurred efficiently at levels over 5% PEI, resulting in the complexes stable in 50% FCS at a PEI-to-iron w/w ratio of ≥7%; the maximum magneto-transduction efficiency was achieved at 9-12%PEI. Primary silica iron oxide nanoparticles and those with 11.5% PEI demonstrated excellent r2* relaxivity values (>600 s-1(mM Fe)-1) for the free and cell-internalized particles. Conclusions: Surface decoration of the silica-iron oxide nanoparticles with a PEI-to-iron w/w ratio of 10-12% yields stable aqueous suspensions, allows for efficient viral gene delivery and labeled cell detection by MRI.
KW - Colloidal stability
KW - MRI relaxivity
KW - Magnetic nanoparticles
KW - Silica-polyethylenimine coating
KW - Transduction
UR - https://www.scopus.com/pages/publications/84862674356
U2 - 10.1007/s11095-011-0661-9
DO - 10.1007/s11095-011-0661-9
M3 - Article
C2 - 22222384
AN - SCOPUS:84862674356
SN - 0724-8741
VL - 29
SP - 1344
EP - 1365
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 5
ER -